# Biochemistry

# <u>⊷</u>©()()() |

Article

# Calorimetric Analysis of the Interplay between Synthetic Tn Antigen-Presenting MUC1 Glycopeptides and Human Macrophage Galactose-Type Lectin

Donella M. Beckwith, Forrest G. FitzGerald, Maria C. Rodriguez Benavente, Elizabeth R. Mercer, Anna-Kristin Ludwig, Malwina Michalak, Herbert Kaltner, Jürgen Kopitz, Hans-Joachim Gabius, and Maré Cudic\*



CLEC10A), a C-type lectin expressed by dendritic cells and macrophages, is a receptor for N-acetylgalactosamine  $\alpha$ -linked to serine/threonine residues (Tn antigen, CD175) and its  $\alpha 2$ ,6-sialylated derivative (sTn, CD175s). Because these two epitopes are among malignant cell glycan displays, particularly when presented by mucin-1 (MUC1), assessing the influence of the site and frequency of glycosylation on lectin recognition will identify determinants governing this interplay. Thus, chemical synthesis of the tandemrepeat O-glycan acceptor region of MUC1 and site-specific threonine glycosylation in all permutations were carried out. Isothermal titration calorimetry (ITC) analysis of the binding of hMGL to this library of MUC1 glycopeptides revealed an enthalpy-driven process and an affinity enhancement of an order of magnitude with an increasing glycan count from 6–8  $\mu$ M for monoglycosylated peptides to 0.6  $\mu$ M for triglycosylated peptide.



ITC measurements performed in  $D_2O$  permitted further exploration of the solvation dynamics during binding. A shift in enthalpy– entropy compensation and contact position-specific effects with the likely involvement of the peptide surroundings were detected. KinITC analysis revealed a prolonged lifetime of the lectin–glycan complex with increasing glycan valency and with a change in the solvent to  $D_2O$ .

he presence of glycans is increasingly interpreted as a means of conveying molecular signals for many (patho)physiological processes "read" by tissue receptors (lectins).<sup>1-6</sup> This already holds true for the smallest sugar epitope, a single saccharide, the Tn antigen, i.e., N-acetylgalactosamine (GalNAc), O-linked in the  $\alpha$ -anomeric bond to Ser/Thr residues, which is abundantly present in mucins such as MUC1.<sup>7-11</sup> A mutation in the molecular chaperone Cosmc that is responsible for ensuring acquisition of the optimal activity of T-synthase, the essential enzyme for Tn elongation by  $\beta$ 1,3-galactosylation, leads to cancer-associated over-expression of Tn antigen.<sup>12,13</sup> Interestingly, the profile of the occupancy of acceptor sites in glycoproteins can vary, and it is tempting to interpret this as establishing switches for affinity regulation when interacting with tissue lectins. Strategically teaming up glycopeptide synthesis with calorimetric analysis of the molecular rendezvous between the ligand and a physiologically relevant tissue lectin is a means to provide answers about the significance of site-specific glycosylation and glycan presentation in clusters. In fact, in the case of mucintype O-glycosylation, a diversity of N-acetylgalactosaminyltransferases gives rise to regions with varying degrees of sugar density; this phenomenon is not yet fully understood in functional terms.<sup>14,15</sup> Toward this end, we here focused on a

GalNAc receptor expressed by macrophages and dendritic cells, the human macrophage galactose-type lectin (hMGL, UniProtKB Q8IUN9).

hMGL belongs to the C-type family of lectins, which recruits  $Ca^{2+}$  for coordination bonding of the ligand.<sup>16,17</sup> Structurally, this immune cell lectin is closely related to the hepatic asialoglycoprotein receptor (ASGPR), with specificity directed toward the Tn antigen<sup>18–21</sup> and its  $\alpha$ 2,6-sialylated derivative.<sup>22,23</sup> The relevance of glycan density with a set of six mono- to hexaglycosylated peptides generated on the platform of the synthetic 11-mer core sequence PTTTPITTTTK<sup>20</sup> and the role of the neighboring peptide backbone portions<sup>21</sup> in recognition by hMGL were described previously. Similarly, evidence of an emerging relevance of the degree of occupancies in mucin (fragments) obtained with leguminous lectins was reported.<sup>24–26</sup> These studies of plant lectins prompted us to

Received:December 4, 2020Revised:January 31, 2021Published:February 9, 2021





perform a detailed analysis of ligand binding with synthetic bioinspired glycopeptides for a human lectin. We first prepared the complete panel of Thr-modified glycopeptides of the MUC1 tandem-repeat motif. In this context, it is noteworthy that comparative analysis of staining profiles of GalNAc-specific lectins from plants (DBA and SBA) or snails (HPA) with that of hMGL in mucin-rich murine jejunum had disclosed differences so that extrapolations between lectins of the same nominal monosaccharide specificity should be done with caution.<sup>27</sup>

Having made the glycopeptides with site-specific glycosylation in systematic permutations to yield mono- to triglycosylated products, available in the first part of our study, we then performed a systematic ITC analysis. It includes examining the effect of glycan site variations at constant valency. To gain further insights into the binding process, we assessed binding thermodynamics in both  $H_2O$  and  $D_2O$  as a means to probe hydration contribution(s); this was studied for the first time with a human C-type lectin, so far exclusively done on leguminous lectins, especially concanavalin A.<sup>28,29</sup> Our applications of ITC and KinITC shed light on differential thermodynamics and kinetics of association among the MUC1 glycopeptides and the carbohydrate recognition domain (CRD) of hMGL that are dependent on the specific site and density of glycosylation, as well as the type of solvent environment.

#### MATERIALS AND METHODS

Reagents and General Procedures. All reagents and solvents were purchased from commercial sources (Thermo Fisher Scientific or Sigma-Aldrich) and used without further purification. Spectra/Por-Float-A-Lyzer dialysis units and Slide-A-Lyzer dialysis cassettes were purchased from Thermo Fisher Scientific. D-Galactal (1), Fmoc-L-threonine (Fmoc-Thr-OH), N,N'-diisopropyl-carbodiimide (DIC), pentafluorophenol (Pfp), and hydroxybenzotriazole (HOBt) were purchased from CHEM-IMPEX. Hydrogen peroxide (30%,  $H_2O_2$ ), anhydrous silver perchlorate (AgClO<sub>4</sub>), molecular sieves (4 Å, 1.6 and/or 3.2 mm), N-acetyl-D-galactosamine (GalNAc), and deuterium oxide (D<sub>2</sub>O) were from Sigma-Aldrich. Methyl N-acetyl- $\alpha$ -D-galactosamine ( $\alpha$ -Me-GalNAc), methyl N-acetyl- $\beta$ -D-galactosamine ( $\beta$ -Me-GalNAc), and methyl  $\beta$ -glucopyranoside ( $\beta$ -Me-Glu) were purchased from Toronto Research Chemicals. The standard Fmoc-protected amino acids and O-(1H-6-chlorobenzotriazol1-yl)-1,1,3,3tetramethyluronium hexafluorophosphate (HCTU) were obtained from Protein Technologies, and Tentagel S RAM Fmoc resin was purchased from Advanced ChemTech. Filter devices used in centrifugation were obtained from Pall Corp.

Reactions were monitored using TLC on 200  $\mu$ m thick silica gel F-254-coated aluminum plates (Silicycle, Inc.) with detection by ultraviolet (UV) light ( $\lambda = 254$  nm) and/or by charring with a 10% solution of sulfuric acid in ethanol. Column chromatography was carried out using Silicycle silica gel F60 (230–400 mesh). <sup>1</sup>H and <sup>13</sup>C NMR spectra were obtained on Varian Mercury 400 MHz or Bruker Advanced III 400 MHz spectrometers. Signals are reported in terms of their chemical shifts ( $\delta$  in parts per million) relative to CDCl<sub>3</sub> (<sup>1</sup>H,  $\delta$ 7.26; <sup>13</sup>C,  $\delta$  77.16). Coupling constants (*J* values) are reported in hertz. All spectra were analyzed using ACD/LABORATO-RIES software.

Synthesis of 2-Azido Tn Antigen Building Block  $N^{\alpha}$ - (9*H*-Fluoren-9-yl)-methoxycarbonyl-O-(3,4,6-tri-O-ace-

tyl-2-azido-2-deoxy- $\alpha$ -D-galactopyranosyl)-L-threonine Pfp Ester (4). Tri-O-acetylated D-galactal (2) was prepared from D-galactal (1) by using acetic anhydride and pyridine as a catalyst, according to the well-established protocol.<sup>30</sup> 3,4,6-Tri-O-acetyl-2-azido-2-desoxy- $\alpha$ -D-galactopyranosyl chloride (3) was synthesized according to the method of Plattner et al.<sup>31</sup> and used in the next glycosylation step without further purification. Compound 3 (1.89 g, 5.40 mmol) and  $N^{\alpha}$ -Fmoc-Thr-OPfp (1.31 g, 2.58 mmol) were dissolved in a mixture of anhydrous DCM (25 mL) and toluene (20 mL), and then the mixture was stirred with activated 4 Å molecular sieves (2.0 g)at -30 °C for 20 min under an argon atmosphere. A solution of AgClO<sub>4</sub> (780 mg, 3.76 mmol) in anhydrous toluene (5 mL) was gradually added to the reaction flask over 15 min. The reaction proceeded at room temperature (rt) for 24 h or until compound 3 was completely consumed, as confirmed by TLC. The reaction mixture was diluted with DCM (75 mL), and the suspension was filtered through a Celite and washed with DI water (200 mL). The organic layer was dried with sodium sulfate (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo before fractionation by column chromatography purification [4:1 (v/v)]toluene/EtOAc] that gave a light-yellow viscous oil (4). The final 2-azido Fmoc-protected O-glycosylated Thr (4) was precipitated in cold petroleum ether affording a white powder, obtained in 71.7% (1.56 g, diastereochemically pure  $\alpha$ anomer) yield and 11.9% (0.26 g,  $\beta$ -anomer) yield. The HPLC chromatogram, MALDI-TOF mass spectrum, and NMR spectrum (<sup>1</sup>H and <sup>13</sup>C) are shown in Figures S1–S4.

Synthesis of Tn Antigen Building Block  $N^{\alpha}$ -(9H-Fluoren-9-yl)-methoxycarbonyl-O-(3,4,6-tri-O-acetyl-2acetamido-2-deoxy- $\alpha$ -D-galactopyranosyl)-L-threonine Pfp Ester (5). To a solution of glacial acetic acid (2.7 mL), acetic anhydride (25 mL), and tetrahydrofuran (THF) (25 mL) was added compound 4 ( $\alpha$ -anomer, 1.17 g, 1.43 mmol), and the mixture was allowed to cool to 0 °C for 15 min before activated zinc powder (1.86 g, 28.44 mmol) was stirred into the mixture and continued to spin overnight at rt. Freshly activated zinc was prepared by successive rapid washings with 3% diluted hydrochloric acid (four times), distilled water (four times), EtOH (four times), and dry diethyl ether (four times) and dried under vacuum overnight. The suspension was quenched with THF (60 mL) and filtered through Celite, and the resulting product was rinsed with EtOAc. The solvents were evaporated azeotropically with toluene before column chromatography purification [1:1 (v/v) toluene/EtOAc]. Recrystallization with cold petroleum ether afforded the white precipitate, Tn antigen (5), obtained in 78.1% (0.93 g, diastereochemically pure  $\alpha$ -anomer) yield. The HPLC chromatogram, MALDI-TOF mass spectrum, and NMR spectrum (<sup>1</sup>H and <sup>13</sup>C) are provided in Figures S5–S8.

Synthesis of MUC1 Tandem-Repeat (Glyco)peptides. Syntheses of MUC1 peptides were completed using the solid phase peptide synthesis (SPPS) approach on Tentagel S RAM Fmoc resin (0.1 mmol scale). Automated peptide synthesis was carried out using a Protein Technologies, Inc., PS3 peptide synthesizer. The Fmoc amino acids and coupling reagents, HCTU and 1-HOBt, were used in 4-fold molar excess. The Pfp ester of the glycoamino acid (5) was coupled manually in a 1.5-fold molar excess in the presence of DIPEA (230  $\mu$ L, 1.32 mmol). Piperidine at a concentration of 20% in DMF was used for Fmoc deprotection reactions. Removal of amino acid side chain protecting groups and release of the peptides from the resin were performed concurrently using a water/thioanisole/ trifluoroacetic acid (TFA) cocktail [2.5:2.5:95 (v/v/v)] while samples were being agitated for 3 h. Peptides were precipitated with cold methyl tert-butyl ether (MTBE) and centrifugated at 4000 rpm for 10 min at 4 °C. The precipitate was suspended in fresh MTBE, centrifugated, and decanted three additional times, successively. Peptides were deacetylated by agitation in a 0.1 M solution of NaOH for 15 min. The pH was adjusted to 4 by dropwise addition of 6 M HCl. The lyophilized crude deacetylated peptide was screened by analytical RP-HPLC and analyzed by MALDI-TOF MS. The crude peptides were purified by a semipreparative RP-HPLC 1260 Infinity Agilent Technologies system using a Grace Vydac monomeric C18 column [250 mm  $\times$  22 mm (inside diameter)] with a 10 mm core-shell particle size (120 Å pore size) as a stationary phase. For elution, a linear gradient with eluent A (0.1% TFA in water) and eluent B (0.08% TFA in acetonitrile) was used at a flow rate of 10 mL/min. Homogeneous fractions were combined, and their purity was evaluated by analytical RP-HPLC on a model 1260 Infinity Agilent Technologies system using a Phenomenex Aeris Peptide XB-C18 column [150 mm  $\times$  4.6 mm (inside diameter)] with a 3.6  $\mu$ m core-shell particle size (100 Å pore size) as a stationary phase. A linear elution gradient (0.5% B at 0 min, 0.5% B at 2 min, and 30% B at 30 min) with eluent A (0.1% TFA in water) and eluent B (0.08% TFA in acetonitrile) was used at a flow rate of 0.8 mL/min. Absorption signals were detected with a UV diode array detector at a wavelength of 214 nm. The collected fractions were analyzed by MALDI-TOF MS (Applied Biosystems Voyager-De Pro) using  $\alpha$ -cyano-4-hydroxycinnamic acid ( $\alpha$ -CHCA) as the matrix. HPLC and MALDI-TOF MS analyses of the purified glycosylated peptides are provided in Figures S10-S25.

**CD of (Glyco)peptides.** The CD spectra were recorded by a JASCO J-810 spectropolarimeter (Jasco, Eaton, MD) and processed using Spectragryph software.<sup>32</sup> Spectra were recorded in the wavelength range of 180–260 nm at 25 °C using a scan speed of 200 nm/min at a 0.1 nm bandwidth in a rectangular quartz cell with a path length of 0.1 cm. The optimum absorbance was obtained with a peptide concentration of 0.13 mg/mL. Molar concentrations of the peptidyl solutions were determined by analytical RP-HPLC; in turn, molar ellipticity values were normalized. CD measurements are presented in [ $\theta$ ] in degrees square centimeter per decimole. Peptides were dissolved in deionized water or heavy water as specified, and the resulting spectra are given in Figure S26.

Lectin Preparation. The lectin's extracellular domain that includes the stalk and three noncovalently associated CRDs (Q8IUN9) was obtained by recombinant production. Protein was isolated from inclusion bodies by steps that involve solubilization, refolding, and purification. The obtained product was then ascertained for purity as described previously.<sup>21,27</sup> To obtain the full-length cDNA sequence of the extracellular domain of hMGL, specific oligonucleotides were designed on the basis of the published sequence in the GSDB, DDBJ, EMBL, and NCBI databases with accession number D50532.<sup>19</sup> The PCR-based amplification was directed using sense primer 5'-CCGGATCCTGGTGACCCTGAG-AAC-3' and antisense primer 5'-CCGGATCCGGGTG-GTCCCACCAA-3' with an internal BamHI restriction site (underlined). The PCR product was separated by agarose gel electrophoresis, eluted from the respective gel slice by using a gel extraction kit (Invitek, Berlin, Germany), digested by BamHI, and finally ligated without a start codon for the inframe insertion into the BamHI-linearized pET-3d vector (Novagen). This process resulted in an N-terminal elongation of the expressed protein sequence of 11 amino acids of the T7 tag (underlined) and one amino acid of the vector backbone before the BamHI restriction side (MASMTGGOOMG R). For plasmid-directed protein expression, Escherichia coli strain BL21 (DE3) cells were transformed with the constructed pET3d-hMGL plasmid and cultured at 37 °C until an optical density of 0.6-0.8 was reached. Optimal protein expression was obtained with terrific broth (TB) medium at 30 °C for 4 h in the presence of isopropyl  $\beta$ -D-thiogalactopyranoside at a final concentration of 0.1 mM. To recover expressed proteins that formed inclusion bodies, cells were harvested by centrifugation (7000  $\times$  g for 10 min) and washed with 50 mM Tris-HCI buffer (pH 8.0) containing 0.15 M NaCl. Cells were frozen for 1 h, resuspended in Tris-buffered saline (TBS) containing 1 mM phenylmethanesulfonyl fluoride (PMSF), and lysed on ice by three cycles of sonication for 1 min each. The bacterial lysate was centrifuged at 39000g and 4 °C for 20 min. The preparation of inclusion bodies and refolding of the active proteins had been described previously.<sup>19,33</sup> In brief, pellets containing the insoluble inclusion bodies were recovered and washed by centrifugation at 14000 rpm for 20 min at 4 °C with 60 mL of TBS containing 0.1% Triton X-100 and 10 mM ethylenediaminetetraacetic acid (EDTA), followed by a wash with 30 mL of  $H_2O$ , and the suspension was finally centrifuged at 39000  $\times$  g for 20 min at 4 °C. Washed pellets were solubilized with 100 mL of 2 M ammonium hydroxide under stirring for 6 h at rt and then dialyzed against 20 mM MOPS buffer (pH 7.0) containing 20 mM CaCl<sub>2</sub> and 0.5 M NaCl at 4 °C. Soluble recombinant hMGL was purified by affinity chromatography on a column of homemade lactose-Sepharose 4B, as described previously.<sup>21</sup>

**Lectin Purity and Structural Status.** Gel electrophoresis and analysis were performed using one- and two-dimensional separation. Isoelectric focusing was conducted on a ZOOM-IPGRunner system (Invitrogen, Carlsbad, CA) with ZOOM strips (pI 4–7 and 3–10). Focusing conditions for the pI 4–7 strips were 175 V for 15 min, 175–2000 V for 45 min, and 2000 V for 105 min. For the pI 3–10 strips, conditions were 175 V for 15 min, 175–2000 V for 45 min, and 2000 V for 30 min. Strips were treated with 125 mM iodoacetamide for protein alkylation. SDS–PAGE under reducing conditions was carried out in an XCell SureLock electrophoresis chamber (Invitrogen) on a NuPAGE Novex 4% to 12% Bis-Tris ZOOM gel at 200 V.

To prepare the protein for gel filtration, lyophilized protein was dissolved in running phosphate-buffered saline (PBS) and 50  $\mu$ L aliquots were chromatographed on a Superose-12HR10/30 column using an ÄKTApurifier 10 system with a flow rate of 0.5 mL/min at 4 °C. Protein elution was recorded at 280 nm. The column was calibrated with the following molecular weight markers: blue dextran ( $M_r > 2000$ kDa), aldolase ( $M_r = 158$  kDa), albumin ( $M_r = 67$  kDa), ovalbumin ( $M_r = 44$  kDa), chymotrypsinogen ( $M_r = 25$  kDa), and vitamin B<sub>12</sub> ( $M_r = 1.35$  kDa).

Matrix-assisted laser desorption ionization (MALDI) timeof-flight (TOF) mass spectrometry (MS) was applied for molecular weight determination and peptide mass fingerprinting using trypsin and chymotrypsin in independent experiments, as described for lectin analysis previously.<sup>34–36</sup> Briefly, each protein sample was dissolved in water to reach a final concentration of 4  $\mu g/\mu L$ ; for molecular mass Scheme 1. Synthetic Procedures for Fmoc-Thr(Tn) Building Block 5 for Use in SPPS<sup>a</sup>



"Reagents and conditions: (a) acetic anhydride, pyridine, DCM, rt, 16 h; (b) FeCl<sub>3</sub>, NaN<sub>3</sub>, H<sub>2</sub>O<sub>2</sub>, ACN, -45 °C, 6 h; (c) DIC, Pfp-OH, EtOAc, -15 °C, 4 h; (d) AgClO<sub>4</sub>, anhydrous DCM/toluene [1:1 (v/v)], -30 °C, 16 h; (e) zinc powder, acetic acid/acetic anhydride/THF [1:6:6 (v/v/v)], rt, 18 h.

determination with double-layer sinapinic acid as the matrix, the protein-containing sample was further diluted with 0.1% TFA [1:5 (v/v)]. For peptide fingerprinting, 5  $\mu$ g of protein was separately digested with either 50 ng of trypsin or 50 ng of chymotrypsin. Digest mixtures were desalted with reversed phase ZipTip<sub>C-18</sub> (Merck, Darmstadt, Germany), and samples spotted on a MALDI target plate with  $\alpha$ -CHCA as a matrix for analysis from Bruker Daltonik (Bremen, Germany). Spotted samples were dried at ambient temperature prior to mass spectrometric analysis. MALDI mass spectra were collected on a RapifleX Tissue Typer instrument (Bruker Daltonik). FlexControl (version 3.4) was used for instrument control, and FlexAnalysis (version 3.4) for processing the data of the spectra. Annotated spectra were further analyzed with BioTools 3.2 (Bruker Daltonik). Enzyme specificity was set to that of trypsin or chymotrypsin, allowing also for cleavage N-terminally to proline residues and up to two missed cleavage sites, or to that of chymotrypsin allowing up to three missed cleavage sites. Carbamidomethylation (CAM) was set as the fixed modification, whereas oxidation of methionine (M) and N-terminal acetylation were considered as variable modifications.

**ITC Experiments.** Microcalorimetric measurements were performed using a MicroCal PEAQ-ITC calorimeter (Malvern) for GalNAc and (glyco)peptides and iTC200 (Microcal) for  $\alpha$ -Me-GalNAc,  $\beta$ -Me-GalNAc, Thr-Tn, and  $\beta$ -Me-Glc. The ligand-containing solution was injected in 2  $\mu$ L aliquots by a computer-controlled microsyringe at 150 s intervals between injections into the solution of lectin buffer (calorimetric cell volume of 200  $\mu$ L) at 25 °C for a total of 19 injections while stirring at 750 rpm. Solutions of the monosaccharide and its derivatives were diluted to concentrations of 1.50 mM, while the solutions of (glyco)peptides were diluted to concentrations

of 0.25-0.50 mM based on analytical RP-HPLC. Lectin concentrations were 11-50  $\mu$ M as confirmed by measurements using a BioTek Epoch microplate spectrophotometer at  $\lambda$  = 280 nm, using the monomer  $\varepsilon$  = 22.9 value for a 1% (w/v) solution. The concentrations of the ligand and lectin for each experiment are provided in the Supporting Information along with the corresponding thermograms (Figures S28-S30). Solutions of both the ligand and the lectin (extracellular domain) were prepared in 10 mM HEPES sodium salt, 50 mM NaCl, and 2 mM CaCl<sub>2</sub> (pH 7.4) in both deionized H<sub>2</sub>O and  $D_2O$  (heavy water, >99.8 atom % D), as shown previously to be practical for human galectins-1 and -3.37 Thermodynamic analysis was performed using MicroCal PEAQ-ITC and Origin analysis software based on a one-set-of-sites model, and with the fitted offset parameter applied to each titration following the company's guideline and previous applications.<sup>38</sup> Thermograms, integrated heat values, and signature plot analysis of the thermodynamic bindings are provided in Figures S28-S30. Additionally, experimental ITC data were processed using NITPIC version 1.2.7 (biophysics.swmed. edu/MBR/software.html),<sup>41,42</sup> fit into a 1:1 binding model using SEDPHAT version 15.2b (sedfitsedphat.nibib.nih.gov), and the output was documented graphically using GUSSI version 1.4.2 (biophysics.swmed.edu/MBR/software.html) (Figure S31).

**Kinetic Parameters.** The application of the KinITC software<sup>43</sup> led to estimations of the off and on rate constants  $[k_{off} \text{ and } k_{on}, \text{ respectively (Figures S32 and S33)]}$ . The commercially available ITC analysis software AFFINImeter version 1.2.3 (affinimeter.com/site/download/affinimeter-itc-windows/) was used in our analysis.<sup>44</sup> Dissociation and association rate constants were obtained from the time-dependent peak shapes determined experimentally by ITC.

Λ	rti.	
	u u	

Table 1. SPPS of MUC1	(Glyco	)peptides	and	Their	Characterization	by	MALDI-TOF	MS	and	RP-H	IPLO	C
-----------------------	--------	-----------	-----	-------	------------------	----	-----------	----	-----	------	------	---

			MALDI-TOF	$MS [M + H]^{+a}$	RP-HPLC
entry	amino acid sequence <sup>b</sup>	no. of sugars	expected (Da)	observed (Da)	$t_{\rm R}^{\ c}$ (min)
6	H-HGVTSAPDTRPAPGSTAPPA-NH <sub>2</sub>	0	1884.93	1885.65	17.42
7	H-HGVT*SAPDTRPAPGSTAPPA-NH <sub>2</sub>	1	2089.25	2088.73	16.34
8	H-HGVTSAPDT*RPAPGSTAPPA-NH <sub>2</sub>	1	2089.25	2088.49	16.85
9	H-HGVTSAPDTRPAPGST*APPA-NH <sub>2</sub>	1	2089.25	2088.44	16.57
10	$\rm H-HGVTSAPDT*RPAPGST*APPA-NH_2$	2	2292.45	2290.19	15.93
11	$\rm H\text{-}HGVT*SAPDTRPAPGST*APPA\text{-}NH_2$	2	2292.45	2291.47	15.38
12	$\mathrm{H}\text{-}\mathrm{H}\mathrm{G}\mathrm{V}\mathrm{T}^{*}\mathrm{S}\mathrm{A}\mathrm{P}\mathrm{D}\mathrm{T}^{*}\mathrm{R}\mathrm{P}\mathrm{A}\mathrm{P}\mathrm{G}\mathrm{S}\mathrm{T}\mathrm{A}\mathrm{P}\mathrm{P}\mathrm{A}\text{-}\mathrm{N}\mathrm{H}_{2}$	2	2292.45	2290.39	15.62
13	H-HGVT*SAPDT*RPAPGST*APPA-NH <sub>2</sub>	3	2495.28	2493.69	15.11
	h				

<sup>*a*</sup>The matrix used was  $\alpha$ -cyano-4-hydroxycinnamic acid. <sup>*b*</sup>T\* is a Thr O-linked Tn monosaccharide. <sup>*c*</sup>HPLC analysis conditions can be found in the Figures S10–S25.

#### RESULTS AND DISCUSSION

Synthesis of Fmoc-Protected O-Glycosylated Thr-Based Building Blocks. The main challenge in the synthesis of the Tn antigen building block stems from the low yield and the achievement of stereoselective formation of the 1,2-cis- $\alpha$ glycoside [4 (Scheme 1; for analytical data, see Figures S1-[58)]. A one-pot azidochlorination method<sup>31</sup> was used to obtain the fully protected 2-azido-2-deoxy-galactopyranosyl chloride donor [3 (Scheme 1); 97% crude yield]. The use of the azidochlorinated carbohydrate moiety enables stereochemically controlled generation of the  $\alpha$ -glycosidic bond due to the nonparticipating nature of the C-2 azido group and the ability of the chloride to act as the leaving group at the anomeric carbon.<sup>45</sup> With access to sufficient quantities of the chloroazide donor (3), a modified Koenigs-Knorr reaction ensued upon incorporation of the Pfp ester of the Fmocprotected Thr acceptor. To minimize formation of the  $\beta$ anomer, the reaction was conducted in noncoordinating cosolvents, and the Fmoc-Thr-OPfp acceptor was used in a limiting amount (0.75 equiv). This strategy exploited the dualpurpose Pfp group, both as a C-terminal acid-protecting group and an activating group during SPPS. Pure  $\alpha$ -glycoside was obtained by gradient elution with toluene and ethyl acetate (EtOAc) in silica gel [4 (Scheme 1); 71.7%  $\alpha$ -anomer yield]. The assumption of formation of the  $\alpha$ -O-glycosidic linkage was confirmed by measuring the characteristic anomeric doublet at 5.18 ppm (at 4.5 ppm expected for the  $\beta$ -proton) and 99.1 ppm for the anomeric carbon (Figures S3 and S4). Using a one-pot reductive acetylation approach in the presence of activated zinc powder, the O-glycosylated Thr azide (4) was converted into the acetamide. This step affords the desired Fmoc-protected Pfp ester of O-glycosylated Thr [5 (Scheme 1); 78.1% yield] after purification by silica gel chromatography. The anomeric purity of the building blocks (4 and 5) was confirmed by analytical RP-HPLC and <sup>1</sup>H and <sup>13</sup>C NMR spectroscopy, and the mass by MALDI-TOF MS (Figures S1-**S8**).

MUC1-Based (Glyco)peptide Synthesis and Characterization. The three Thr residues in the MUC1 tandem repeat are acceptors for *O*-glycans. The peptide was used as a platform for the site-specific introduction of  $\alpha$ -linked GalNAc to achieve all Thr-linked permutations for a systematic study. The panel of seven glycopeptides covering the range from single-site to fully glycosylated scaffolds was prepared by SPPS [7–13 (Table 1 and Figure S9)], together with the glycan-free control peptide (6). Fmoc-protected amino acids with HCTU/HOBt activation in equimolar quantities (4-fold excess) were used in an iterative process on an automated peptide synthesizer (Figure S9). The coupling of the orthogonally protected  $\alpha$ -linked GalNAc building block (S) in a 1.5 equiv excess led to the three monoglycosylated peptides (7–9), the three diglycosylated peptides (10–12), and the single triglycosylated peptide (13) (Table 1 and Scheme 1). After completion of the (glyco)peptide chain synthesis, they were cleaved from the resin under acidic conditions (water/thioanisole/TFA), followed by complete removal of the *O*-acetyl (protecting) groups under basic conditions (0.1 M aqueous NaOH). The preparations were processed by RP-HPLC, and their purity was ascertained by analytical RP-HPLC and MALDI-TOF MS (Table 1 and Figures S10–S25).

As expected, upon performance of RP-HPLC, the control peptide (6) displayed the longest retention time  $(t_R)$ . The addition of a single (hydrophilic) glycan moiety at either Thr4, Thr9, or Thr16 (7, 8, or 9, respectively) resulted in a decrease in  $t_R$  by 1 min (on average), followed by a further 1 min decrease for the diglycosylated peptides (10–12). The triglycosylated peptide (13) eluted from the column first, almost 3 min earlier than the nonglycosylated peptide (6) (Table 1). It is noteworthy that a separation among mono- or diglycosylated peptides that differ in the position of the glycan attachment site was detected (Table 1). Under these conditions, the tertiary structure of a peptide is assumed to be disrupted during RP-HPLC, either by the solvents used for elution and/or due to interaction of the peptide with the hydrophobic stationary material.<sup>46</sup>

With the (glyco)peptides (6–13) in hand, their secondary structure could be investigated by circular dichroism (CD) spectroscopy. No significant differences in the overall conformations were observed in either H<sub>2</sub>O or buffered D<sub>2</sub>O (Figure S26). A random coil with polyproline II (PPII) helical elements present was observed, as indicated by the spectral molar ellipticity ( $[\theta]$ ) minima at 198 nm and the increased maximum ( $[\theta]_{max}$ ) intensity at 222 nm.<sup>47</sup> It is noteworthy that the extent of the presence of structured elements positively correlates to GalNAc density (Figure S26). These findings correlate well with the corresponding decrease in  $t_R$  on RP-HPLC (Table 1). This panel of glycopeptides could next be used as ligands for the endogenous lectin.

hMGL Lectin Purification and Characterization. The protein's purity was assessed by one- and two-dimensional gel electrophoresis analyses (Figure 1A–C) using human galectin-3 (Figure 1A) and galectin-1 (Figure 1C) as internal standards due to the similar properties of the mass/isoelectric point as well as by mass spectrometry of intact and proteolytically



**Figure 1.** Characterization of hMGL by SDS–PAGE, two-dimensional (2D) gel electrophoresis, and gel filtration. (A) SDS–PAGE (15% polyacrylamide) of 0.1, 0.5, and 1.0  $\mu$ g of hMGL as well as 0.2  $\mu$ g of galectin-3 (protein with a similar mass and constitution with stalk and CRD). (B) 2D gel electrophoresis of 20  $\mu$ g of hMGL in the pI range of 3–10. (C) 2D electrophoresis of a mixture of 20  $\mu$ g of hMGL and 20  $\mu$ g of galectin-1 in the pI range of 4–7. (D) Gel filtration of hMGL at the indicated concentrations (applied volume of 50  $\mu$ L in each case).

cleaved material (Figure S27A–D). Gel filtration analysis (elution profiles shown in Figure 1D) revealed the typical asymmetrical peak so that, in line with previous work, these results "are consistent with the presence of a dissociating trimer".<sup>48</sup>

**ITC Titrations in H<sub>2</sub>O.** As an internal reference for the work with the glycopeptides, ITC titrations were first performed in H<sub>2</sub>O with free GalNAc (Figure 2A), its  $\alpha/\beta$ -

methyl derivatives, and the Thr-GalNAc conjugate. In each case, titration reached full saturation with an *n* value consistently around 1, when *n* is normalized to the active cell concentration of the dissociating trimer. The  $K_D$  values were in the range of 10  $\mu$ M (Figure S29). Expectedly, there was no indication of a detectable affinity for methyl  $\beta$ -glucopyranoside used as a negative (specificity) control with hMGL. The  $\alpha$ -methyl anomer (present in mucins) yielded an affinity that was 2-fold higher than that of its  $\beta$ -anomer (present in the disaccharide LacdiNAc) presented by *N*-glycan chains of cognate glycoproteins<sup>49</sup> and the GalNAc $\alpha$ 1-O-Thr conjugate (Figure S29). Binding of the monosaccharide, its methyl derivatives, and the conjugate with Thr was enthalpy driven in each case, a common feature of association of glycan to a lectin.

A panel of synthetic MUC1 glycopeptides were tested as ligands for hMGL. The derived stoichiometry (Table 2) revealed the functional valence of MUC1 glycopeptides, defined as the inverse of the obtained n value (1/n). For example, the n value for MUC1-Thr4,9,16 is determined to be 0.32, equating to a maximum of three glycans binding to the trimeric hMGL protein under saturation conditions.

When proceeding to performing thermodynamic analysis of binding the glycopeptide to hMGL, we determined the glycanfree peptide lacks affinity for the lectin. The presence of a GalNAc residue was essential for binding (Table 2, Figure 2B– D, and Figure S29). The affinity increased from a  $K_D$  value of approximately 16–17  $\mu$ M for free GalNAc and the GalNAc $\alpha$ 1-O-Thr conjugate to 7–8  $\mu$ M for the monoglycosylated peptides. Evidently, the peptide backbone presence matters but the nature of the microenvironment of each GalNAc residue (at Thr4, Thr9, or Thr16) has only a minor influence under these conditions.

Moving from monovalent to bivalent and trivalent glycopeptides, the affinity increased markedly to  $K_D$  values of  $\leq 1 \ \mu$ M. The magnitude of this effect was calculated by the affinity enhancement factor  $\beta$  using eq 1.<sup>50</sup>

$$\beta = K_{\rm A}^{\rm multi} / K_{\rm A}^{\rm mono} \tag{1}$$

The highest enhancement value ( $\beta$ ) was obtained for the triglycosylated MUC1-Thr4,9,16 peptide (13) (Table 3). The three individual binding steps exhibit negative cooperativity evidenced by cooperativity coefficient ( $\alpha$ ) values of <1 (Table 3). Upon characterization of the thermodynamics of glycopeptide binding with stepwise increases in valency from one to three, proportional enhancement of  $\Delta H$ , increased negative cooperativity, and increased entropic penalties were observed (Tables 2 and 3).

In terms of drawing an analogy, the spatial presentation of each GalNAc moiety of a single glycopeptide can be viewed to resemble that of terminal contact sites of a triantennary *N*-glycan (Gal/GalNAc) binding to the CRDs of the trimeric ASGPR.<sup>51</sup> The approximate distances between amino acids Thr4 and Thr9 (15.5 Å), Thr9 and Thr16 (21.7 Å), and Thr4 and Thr16 (37.2 Å) calculated from known PPII amino acid distances<sup>52</sup> mimic that of the triantennary *N*-glycan, showing that glycoclusters can avidly interact with hMGL, as also revealed by measuring respective IC<sub>50</sub> values.<sup>53</sup>

We further analyzed our ITC data by the KinITC method.<sup>43</sup> Dissociation and association rate constants ( $k_{off}$  and  $k_{on}$ , respectively) were derived from the ITC titration curve data. The applicability of the method has recently been documented experimentally by running surface plasmon resonance (SPR)



#### pubs.acs.org/biochemistry



**Figure 2.** Selected ITC binding curves, including thermographic profiles for interaction of (A) GalNAc (1.50 mM) with hMGL (29.6  $\mu$ M), (B) MUC1-Thr16 (0.50 mM) with hMGL (22  $\mu$ M), (C) MUC1-Thr4,16 (0.50 mM) with hMGL (20  $\mu$ M), and (D) MUC1-Thr4,9,16 (0.25 mM) with hMGL (20  $\mu$ M) in buffered H<sub>2</sub>O determined by ITC. Isotherms and thermograms were reproduced in GUSSI version 1.4.2 from the data obtained by MicroCal PEAQ-ITC software.

Table 2. ITC Data for Association of hMGL with GalNAc and MUC1-Based Glycopeptides in Buffered H<sub>2</sub>O and D<sub>2</sub>O<sup>a</sup>

		$K_{\rm A}$ (×1	$0^4 M^{-1}$ )	$\Delta G$ (kca	l mol <sup>-1</sup> )	$\Delta H$ (kca	al mol <sup>-1</sup> )	$\Delta - (kcal)$	$T\Delta S$ ) mol <sup>-1</sup> )	1	n	$K_{\rm D}$ (	uM)
ligand	entry	H <sub>2</sub> O	D <sub>2</sub> O	H <sub>2</sub> O	D <sub>2</sub> O	H <sub>2</sub> O	D <sub>2</sub> O	H <sub>2</sub> O	D <sub>2</sub> O	H <sub>2</sub> O	D <sub>2</sub> O	H <sub>2</sub> O	$D_2O$
GalNAc		5.64	13.79	-6.49	-7.01	-11.30	-6.81	4.81	-0.20	0.99	0.97	17.70	7.25
MUC1-Thr4	7	14.66	26.88	-7.05	-7.41	-11.40	-12.50	4.38	5.13	0.99	1.00	6.82	3.72
MUC1-Thr9	8	11.87	10.84	-6.93	-6.87	-10.50	-14.10	3.53	7.22	1.01	1.01	8.42	9.22
MUC1-Thr16	9	14.47	16.75	-7.05	-7.13	-10.00	-14.18	2.95	7.63	1.03	1.01	6.91	5.97
MUC1-Thr9,16	10	81.30	263.15	-8.07	-8.76	-24.00	-19.20	16.00	10.40	0.46	0.49	1.23	0.38
MUC1-Thr4,16	11	144.92	263.15	-8.41	-8.76	-22.80	-24.60	14.30	15.80	0.48	0.50	0.69	0.38
MUC1-Thr4,9	12	70.92	144.50	-7.98	-8.41	-20.70	-15.60	12.70	7.22	0.50	0.50	1.41	0.69
MUC1-Thr4,9,16	13	166.67	338.98	-8.49	-8.91	-30.30	-28.50	21.80	19.50	0.32	0.32	0.60	0.29

<sup>*a*</sup>Errors in  $\Delta H$  ranged between  $\pm 0.01$  and 1.12 kcal mol<sup>-1</sup> and between  $\pm 0.01$  and  $0.61 \ \mu$ M/experiment for  $K_D$ . The error values and concentrations of the ligand and lectin for each experiment are provided in the Supporting Information along with the corresponding thermograms (Figures S28–S30).

#### Table 3. Enhancement Factors ( $\beta$ ) and Cooperativity Coefficients ( $\alpha$ ) for Multivalent MUC1 Glycopeptides<sup>*a*</sup>

ligand	entry	β	α
MUC1-Thr9,16	10	6.17	0.57
MUC1-Thr4,16	11	9.94	0.59
MUC1-Thr4,9	12	5.34	0.57
MUC1-Thr4,9,16	13	12.20	0.40

 ${}^{\alpha}\beta$  enhancement factor values are calculated using the equation  $\beta = K_{\rm A}^{\rm mult/}/K_{\rm A}^{\rm mono}$ .  $\beta$  measures the increase in the affinity of each ligating unit obtained by its multivalent presentation. Cooperativity values ( $\alpha$ ) are calculated using the equation  $\Delta G^{\rm mul,n} = \alpha n \Delta G^{\rm mono}$ . An  $\alpha$  of >1 indicates positive cooperativity in the multivalent interaction, and an  $\alpha$  of <1 indicates negative cooperativity in the multivalent interaction.  $^{50}$  The  $\Delta G^{\rm mono}$  values were calculated by averaging the respective  $\Delta G$  values of the glycan regions being evaluated.

experiments in parallel to ITC to study the thermodynamics and kinetics of binding of mannoside to the fimbrial adhesin FimH.<sup>54</sup> In our study, a fit of the  $k_{on}$  and  $k_{off}$  rates was not possible across the entire set of data (Table 4). Previously published data using SPR had already disclosed this problem for the case of Tn, sTn, and NeuSGc-Tn.<sup>22</sup> The occurrence of this phenomenon may suggest that the free sugar and the Table 4. Kinetic Parameters and Lifetime Calculations of GalNAc and Glycopeptides in Buffered H<sub>2</sub>O When Binding to hMGL<sup>a</sup>

ligand	entry	$k_{\rm on}~(\times 10^6~{\rm M}^{-1}~{\rm s}^{-1})$	$k_{\rm off}~({\rm s}^{-1})$	$\tau$ (s)
GalNAc		-	-	-
MUC1-Thr4	7	-	-	-
MUC1-Thr9	8	-	-	-
MUC1-Thr16	9	0.096	0.600	1.67
MUC1-Thr9,16	10	0.032	0.049	20.41
MUC1-Thr4,16	11	0.058	0.051	19.61
MUC1-Thr4,9	12	0.016	0.060	16.67
MUC1-Thr4,9,16	13	0.026	0.019	52.63

<sup>*a*</sup>Kinetic information was calculated from experimental ITC data using AFFINImeter KinITC software.<sup>44</sup> Lifetimes were calculated using the equation: lifetime ( $\tau$ ) = 1/ $k_{\rm off}$ . The standard errors of  $k_{\rm off}$ and  $k_{\rm on}$  values and the equilibration time curves can be found in Figure S32.

monovalent glycopeptides MUC1-Thr4 and MUC1-Thr9 have relatively high dissociation rates ( $k_{\rm off}$ ), so that ligand—hMGL complexes will have very short lifetimes ( $\tau$ ), defined as the reciprocal of  $k_{\rm off}$ . Fittingly, we were able to record a  $k_{\rm on}$  rate of 0.096  $\times$  10<sup>6</sup> M<sup>-1</sup> s<sup>-1</sup> for binding of hMGL to the

monoglycosylated MUC1-Thr16 peptide (Table 4 and Figure S32).

In this context, upon examination of a member of another class of C-type lectins, association rate constants in the range of  $10^5-10^6$  M<sup>-1</sup> s<sup>-1</sup> have been reported for selectin binding to *in vivo* ligands, i.e., L-selectin to P-selectin glycoprotein ligand-1 (PSGL-1, CD162).<sup>55</sup> Also of interest for comparison, the dissociation rate  $k_{off}$  of 0.060 s<sup>-1</sup> for the MUC1-Thr16 glycopeptide-hMGL complex is similar to  $k_{off}$  values obtained for binding using optical tweezers<sup>56</sup> and indicates a longer lifetime ( $\tau = 1.67$  s) in comparison to those of GalNAc and the two other monoglycosylated peptides. In our experimental series, the triglycosylated MUC1 peptide (13) exhibited the lowest dissociation rate ( $k_{off} = 0.019$  s<sup>-1</sup>) and the longest lifetime of all complexes ( $\tau = 52.63$  s) (Table 4).

In overview, the lifetimes ranged from 1.67 s for the monoglycosylated (7-9) and 16.67-20.41 s for diglycosylated (10-12) to the mentioned value of 52.63 s for the triglycosylated MUC1 peptide (13). To better analyze the solvent contribution to thermodynamics, the measurements in H<sub>2</sub>O were supplemented by work in D<sub>2</sub>O, especially important in resolving cases of extended ligand structures (peptide portion), beyond the direct contact site contributing to binding.

**ITC Titrations in D<sub>2</sub>O.** The thermodynamic parameters in D<sub>2</sub>O are listed in Table 2 and shown in Figure S30. They were then further used to calculate  $\Delta\Delta H$ ,  $\Delta - (T\Delta S)$ , and  $\Delta\Delta G$  values (Table 5). Equation 2 was applied to examine the

Table 5. DIE Parameters of Association for GalNAc and Glycopeptides in  $H_2O$  versus  $D_2O$  (DIE =  $H_2O - D_2O$ ) with hMGL

ligand	entry	$\Delta\Delta G$ (kcal mol <sup>-1</sup> )	$\Delta\Delta H$ (kcal mol <sup>-1</sup> )	$\Delta - (T\Delta S)$ (kcal mol <sup>-1</sup> )
GalNAc		0.52	-4.49	5.01
MUC1-Thr4	7	0.36	1.10	-0.75
MUC1-Thr9	8	-0.06	3.60	-3.69
MUC1-Thr16	9	0.08	4.18	-4.68
MUC1-Thr9,16	10	0.69	-4.80	5.60
MUC1-Thr4,16	11	0.35	1.80	-1.50
MUC1-Thr4,9	12	0.43	-5.10	5.48
MUC1-Thr4,9,16	13	0.42	-1.80	2.30

occurrence of deuterium isotope effects (DIEs). Considering a 10% change in the energy for a hydrogen bond in  $D_2O$  versus  $H_2O$ , this energy difference helps estimate the contribution of solvent reorganization to the observed enthalpy of binding.<sup>28,29,57</sup>

$$\mathrm{DIE}^{\mathrm{H}-\mathrm{D}} = \mathrm{H}_{2}\mathrm{O} - \mathrm{D}_{2}\mathrm{O} \tag{2}$$

Compensation between  $\Delta\Delta H$  and  $\Delta - (T\Delta S)$  afforded a small net change in  $\Delta\Delta G$  (Table 5). The enthalpy of binding for the free glycan to hMGL was less favorable in D<sub>2</sub>O ( $\Delta\Delta H = -4.49$ kcal mol<sup>-1</sup>). This suggests a significant contribution of solvent reorganization to the enthalpy of binding. Such a scenario had previously been seen for the leguminous lectin concanavalin A, in which Ca<sup>2+</sup> does not directly contact the sugar but assists the amino acids in acquiring the suited orientations for mannose binding.<sup>28,29</sup> The data are the first results of a human tissue lectin employing Ca<sup>2+</sup> by engaging in coordination bonds for ligand binding.

When proceeding from using the free sugar to applying glycopeptides, we found the H/D exchange in solvent for the monoglycosylated peptides (7-9) resulted in more favorable enthalpic contributions, accompanied by compensating higher entropic penalties. Evidently, the presence of the peptide backbone and the site of glycan presentation affected solvation differently. The nature of the microenvironment matters. The enthalpy component of MUC1-Thr16 (9) was most affected by the isotope substitution ( $\Delta\Delta H = 4.18 \text{ kcal mol}^{-1}$ ) (Table 5). Thermodynamic parameters of binding the diglycosylated MUC1-Thr4,16 glycopeptide (11) complement the trend seen with the monoglycosylated MUC1 peptides (Table 5). The  $\Delta\Delta G$  values for the MUC1 glycopeptides (7–13) do not significantly change in H<sub>2</sub>O or D<sub>2</sub>O due to the equally compensating behavior observed in  $-T\Delta S$  values (Table 5). The observed variations in the enthalpy component of the DIE further suggest that not only the entire peptide backbone but also the glycan density and the nature of the glycan vicinity impact solvation when in contact with hMGL.

When processing the data to obtain kinetic values, we found an overall increase in the lifetime for lectin–glycopeptide complexes in  $D_2O$  (Figure S33) over that in  $H_2O$  (Table 4). Such an increased lifetime may reflect a slower proton transfer rate between the ligand bound to the lectin than when free in the solvent.<sup>58</sup> This is most evident in the case of the diglycosylated glycopeptide MUC1-Thr4,16 (11).



Figure 3. Left and middle plots showing enthalpy–entropy compensation for hMGL–glycopeptide interaction in (A)  $H_2O$  and (B)  $D_2O$ . The enthalpy and entropy from each of the individual experiments for the glycopeptides binding with hMGL are plotted. Numbered points indicate individual measurements (see Table 2 for point identification). A linear fit to all of the data points yielded lines with slopes of -1.077 and -1.131 for the glycopeptides in  $H_2O$  and  $D_2O$ , respectively. Panel C shows transfer between the two solvents. Enthalpy–entropy compensation for the transfer from  $H_2O$  to  $D_2O$  yielded a line with a slope of -0.92.

Overall, the enthalpy–entropy compensation (EEC) plot in  $D_2O$  displays a linear relationship with a slope near unity (Figure 3B). The data imply that solvent reorganization is a key factor of binding when coordination bonds are involved, and this also has been shown to be effective for antibodyantigen binding.<sup>59</sup> In comparison to the EEC in water (Figure 3A), similar values near unity between the two isosteres are indicative of comparable binding mechanisms operative in both systems. Furthermore, the (compensation) plot of  $\Delta - (T\Delta S)$  (H<sub>2</sub>O-D<sub>2</sub>O) against  $\Delta \Delta H$  (H<sub>2</sub>O-D<sub>2</sub>O) shows an excellent fit to the regression line with a near unity slope (-0.92) and a very small intercept  $(0.20 \text{ kcal mol}^{-1})$  with a correlation coefficient of 0.997 (Figure 3C). These results suggest that the discrepancy in conformational/structural changes taking place in the two solvents is likely minor, and that the (de)hydration processes appear to be a notable source of variety for thermodynamic parameters in this system.

# CONCLUSIONS

Synthesis of the MUC1 glycopeptide panel, based on the tandem-repeat motif, allowed for the thermodynamics of their interactions with hMGL to be determined in a systematic manner. An increased affinity, reaching  $K_D$  values below 1  $\mu$ M with negative cooperativity and with enthalpy-entropy compensation, was determined upon bi- and triglycosylation. KinITC analysis of the ITC data revealed notable decreases in  $k_{\rm off}$  rates with increases in valency. Lifetimes of the hMGLligand complexes reached 52.63 s for the triglycosylated MUC1 peptide (13) in comparison to 1.67 s for the monoglycosylated (at Thr16) peptide. This is in line with a "bind and jump" mechanism originally proposed for binding of proteins to DNA and leguminous lectin binding to mucin or fragments thereof.<sup>60</sup> The noted decrease in the affinity of free (monomeric) CRD and the gradient change in affinity in correlation with glycan density measured by fluorescence polarization equilibrium binding assays<sup>20</sup> relative to trimeric hMGL also argue along this line and call for calorimetric analysis with the CRD, in both H<sub>2</sub>O and D<sub>2</sub>O. Interestingly, in comparison to interaction analysis with leguminous lectins in  $D_2O_1^{28}$  the enthalpy contribution on DIE for MUC1 glycopeptides as ligands varied. These results suggest that features of the peptide backbone likely come into play and impact solvation beyond the cognate sugar for hMGL. Testing sTn as a ligand will broaden the analysis of this aspect. Of relevance in this context, extending the length of a canonical disaccharide ligand to two tetrasaccharides had recently revealed major solvent rearrangements to occur in the case of human galectins-1 and -3.<sup>37</sup> Finally, testing these glycopeptides as antigens will allow comparative thermodynamic studies with antibodies to be performed.

# ASSOCIATED CONTENT

#### Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.biochem.0c00942.

RP-HPLC chromatograms, MALDI-TOF mass spectra, NMR spectra, CD spectra, ITC titration profiles, Affinimeter/KinITC data, and NITPIC/SEDPHAT data (PDF)

Accession Codes hMGL, UniProtKB Q8IUN9.

#### AUTHOR INFORMATION

#### **Corresponding Author**

Maré Cudic – Department of Chemistry and Biochemistry, Charles E. Schmidt College of Science, Florida Atlantic University, Boca Raton, Florida 33431, United States;
orcid.org/0000-0002-7657-0400; Phone: (561) 297-4645; Email: mcudic@fau.edu

# Authors

- **Donella M. Beckwith** Department of Chemistry and Biochemistry, Charles E. Schmidt College of Science, Florida Atlantic University, Boca Raton, Florida 33431, United States
- Forrest G. FitzGerald Department of Chemistry and Biochemistry, Charles E. Schmidt College of Science, Florida Atlantic University, Boca Raton, Florida 33431, United States
- Maria C. Rodriguez Benavente Department of Chemistry and Biochemistry, Charles E. Schmidt College of Science, Florida Atlantic University, Boca Raton, Florida 33431, United States
- Elizabeth R. Mercer Department of Chemistry and Biochemistry, Charles E. Schmidt College of Science, Florida Atlantic University, Boca Raton, Florida 33431, United States
- Anna-Kristin Ludwig Ludwig-Maximilians-University Munich, Institute of Physiological Chemistry, Faculty of Veterinary Medicine, 80539 Munich, Germany
- Malwina Michalak Department of Applied Tumor Biology, Institute of Pathology, Medical School of the Ruprecht-Karls-University Heidelberg, 69120 Heidelberg, Germany
- Herbert Kaltner Ludwig-Maximilians-University Munich, Institute of Physiological Chemistry, Faculty of Veterinary Medicine, 80539 Munich, Germany
- Jürgen Kopitz Department of Applied Tumor Biology, Institute of Pathology, Medical School of the Ruprecht-Karls-University Heidelberg, 69120 Heidelberg, Germany
- Hans-Joachim Gabius Ludwig-Maximilians-University Munich, Institute of Physiological Chemistry, Faculty of Veterinary Medicine, 80539 Munich, Germany; orcid.org/0000-0003-3467-3900

Complete contact information is available at: https://pubs.acs.org/10.1021/acs.biochem.0c00942

#### **Author Contributions**

D.M.B. conducted the synthesis of the building blocks, synthesis of glycopeptides, and their CD analysis. E.R.M. assisted in building block synthesis. F.G.F., D.M.B., and M.C.R.B. conducted and analyzed the ITC experiments. D.M.B. analyzed the kinetic data. A.-K.L. and H.K. conducted lectin preparation. M.M. and J.K. performed purity assessments and gel filtration. M.C. and H.-J.G. supervised experiments and validated results. D.M.B., F.G.F., H.-J.G., and M.C. contributed in writing the manuscript.

# Funding

This research was supported by start-up funds, Florida Atlantic University (FAU), to M.C., National Institutes of Health (NIH) Grant CA242351 to M.C., a FAU Graduate Research and Inquiry Program (GRIP) grant to D.M.B., and FAU OURI Undergraduate Research grants to F.G.F. and E.R.M. Support by COST Action CA18103 (InnoGly; to H.-J.G.) is also gratefully acknowledged.

#### Article

#### Notes

The authors declare no competing financial interest. All data generated or analyzed during this study are included in this published article (and its Supporting Information).

### ACKNOWLEDGMENTS

The authors are thankful to Stoyan Milev (Malvern Panalytical) and Juan Sabin and Adrian Velazquez-Campoy (Affinimeter) for valuable discussions on data analysis software used in this study.

# ABBREVIATIONS

MUC, mucin; Tn, T antigen nouvelle; sTn, sialyl-T antigen nouvelle; hMGL, human macrophage galactose-type lectin; PPII, polyproline II; ITC, isothermal titration calorimetry; CD, circular dichroism; CRD, carbohydrate recognition domain; SPPS, solid phase peptide synthesis; Fmoc, fluorenyl methoxycarbonyl; Pfp, pentafluorophenyl; EtOAc, ethyl acetate; EtOH, ethanol;  $K_D$ , dissociation constant;  $D_2O$ , deuterium oxide; <sup>1</sup>H, hydrogen-1; <sup>13</sup>C, carbon-13;  $\alpha$ -CHCA,  $\alpha$ -cyano-4-hydroxycinnamic acid; CDCl<sub>3</sub>, deuterochloroform;  $\delta_i$ , chemical shift;  $J_i$ , spin-spin splitting; RP, reverse phase; DCM, methylene chloride; AgClO<sub>4</sub>, silver perchlorate; DI, deionized; Na<sub>2</sub>SO<sub>4</sub>, sodium sulfate; NaHCO<sub>3</sub>, sodium bicarbonate; HOBt, hydroxybenzotriazole; HCTU, O-(1H-6chlorobenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; NMM, N-methylmorpholine; DMF, dimethylformamide; DIPEA, N,N-diisopropylethylamine; NaOH, sodium hydroxide; HCl, hydrochloric acid; *n*, number of binding sites; MTBE, methyl *tert*-butyl ether;  $\lambda$ , wavelength; H<sub>2</sub>O<sub>2</sub>, hydrogen peroxide; DIPEA, N,N-diisopropylethylamine; DIC, diisopropylcarbodiimide; NaN<sub>3</sub>, sodium azide; FeCl<sub>3</sub>, iron(III) chloride hexahydrate; Ac<sub>2</sub>O, acetic anhydride; NaCl, sodium chloride; CaCl<sub>2</sub>, calcium chloride; CuSO<sub>4</sub>, copper sulfate; Pyr, pyridine; AcOH, acetic acid; OH, hydroxyl; H/D, hydrogen/ deuterium exchange; DIE, deuterium isotope effect; NMR, nuclear magnetic resonance; RP-HPLC, reverse phase highperformance liquid chromatography; MALDI-TOF MS, matrix-assisted laser desorption ionization time-of-flight mass spectroscopy;  $k_{off}$  dissociation rate;  $k_{on}$ , association rate; EEC, enthalpy–entropy compensation;  $\Delta\Delta H$ ,  $\Delta H^{\rm H_2O} - \Delta H^{\rm D_2O}$ ;  $\Delta - (T\Delta S), - (T\Delta S)^{\rm H_2O} - (T\Delta S)^{\rm D_2O}; \Delta\Delta G, \Delta G^{\rm H_2O} - \Delta G^{\rm D_2O};$ ASGPR, asialoglycoprotein receptor; FimH, fimbrial adhesin; SPR, surface plasmon resonance; PSGL-1, P-selectin glycoprotein ligand-1; Neu5Gc, N-glycol(o)ylneuraminic acid;  $\beta$ , affinity enhancement factor; LacdiNAc, GalNAcβ1,4GlcNAc, N-[(3R,4R,5S,6R)-5-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,4-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide;  $\tau$ , lifetime; DBA, Dolichos biflorus agglutinin; SBA, soybean agglutinin; HPA, Helix pomatia agglutinin; EDTA, ethylenediaminetetraacetic acid; cDNA, complementary DNA; PCR, polymerase chain reaction; TB, terrific broth; IPTG, isopropyl  $\beta$ -D-thiogalactopyranoside; TBS, Tris-buffered saline; PMSF, phenylmethanesulfonyl fluoride; NH4OH, ammonium hydroxide; MOPS, 3-(N-morpholino)propanesulfonic acid; pI, isoelectric point; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; PBS, phosphate-buffered saline; Mr, relative molar mass; CAM, carbamidomethylation.

## REFERENCES

(1) Kaltner, H., Abad-Rodríguez, J., Corfield, A. P., Kopitz, J., and Gabius, H.-J. (2019) The sugar code: letters and vocabulary, writers,

editors and readers and biosignificance of functional glycan-lectin pairing. *Biochem. J.* 476, 2623–2655.

(2) Manning, J. C., Romero, A., Habermann, F. A., García Caballero, G., Kaltner, H., and Gabius, H.-J. (2017) Lectins: a primer for histochemists and cell biologists. *Histochem. Cell Biol.* 147, 199–222.
(3) Corfield, A. (2017) Eukaryotic protein glycosylation: a primer for histochemists and cell biologists. *Histochem. Cell Biol.* 147, 119–147

(4) Gabius, H.-J., and Roth, J. (2017) An introduction to the sugar code. *Histochem. Cell Biol.* 147, 111–117.

(5) Cummings, R. D. (2019) Stuck on sugars - how carbohydrates regulate cell adhesion, recognition, and signaling. *Glycoconjugate J. 36*, 241–257.

(6) Beckwith, D. M., and Cudic, M. (2020) Tumor-associated *O*-glycans of MUC1: carriers of the glyco-code and targets for cancer vaccine design. *Semin. Immunol.* 47, 101389.

(7) Chugh, S., Gnanapragassam, V. S., Jain, M., Rachagani, S., Ponnusamy, M. P., and Batra, S. K. (2015) Pathobiological implications of mucin glycans in cancer: sweet poison and novel targets. *Biochim. Biophys. Acta* 1856, 211–225.

(8) Corfield, A. P. (2015) Mucins: a biologically relevant glycan barrier in mucosal protection. *Biochim. Biophys. Acta, Gen. Subj.* 1850, 236–252.

(9) Ju, T., Otto, V. I., and Cummings, R. D. (2011) The Tn antigenstructural simplicity and biological complexity. *Angew. Chem., Int. Ed. 50,* 1770–1791.

(10) Cervoni, G. E., Cheng, J. J., Stackhouse, K. A., Heimburg-Molinaro, J., and Cummings, R. D. (2020) *O*-glycan recognition and function in mice and human cancers. *Biochem. J.* 477, 1541–1564.

(11) Stowell, S. R., Ju, T., and Cummings, R. D. (2015) Protein glycosylation in cancer. *Annu. Rev. Pathol.: Mech. Dis.* 10, 473–510.

(12) Wang, Y., Ju, T., Ding, X., Xia, B., Wang, W., Xia, L., He, M., and Cummings, R. D. (2010) Cosmc is an essential chaperone for correct protein O-glycosylation. *Proc. Natl. Acad. Sci. U. S. A.* 107, 9228–9233.

(13) Ju, T., Lanneau, G. S., Gautam, T., Wang, Y., Xia, B., Stowell, S. R., Willard, M. T., Wang, W., Xia, J. Y., Zuna, R. E., Laszik, Z., Benbrook, D. M., Hanigan, M. H., and Cummings, R. D. (2008) Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. *Cancer Res.* 68, 1636–1646.

(14) Bennett, E. P., Mandel, U., Clausen, H., Gerken, T. A., Fritz, T. A., and Tabak, L. A. (2012) Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. *Glycobiology* 22, 736–756.

(15) Raman, J., Guan, Y., Perrine, C. L., Gerken, T. A., and Tabak, L. A. (2012) UDP-*N*-acetyl- $\alpha$ -D-galactosamine:polypeptide *N*-acetylgalactosaminyltransferases: completion of the family tree. *Glycobiology* 22, 768–777.

(16) Drickamer, K., and Taylor, M. E. (2015) Recent insights into structures and functions of C-type lectins in the immune system. *Curr. Opin. Struct. Biol.* 34, 26–34.

(17) Gabius, H.-J., Kaltner, H., Kopitz, J., and André, S. (2015) The glycobiology of the CD system: a dictionary for translating marker designations into glycan/lectin structure and function. *Trends Biochem. Sci.* 40, 360–376.

(18) Ozaki, K., Lee, R. T., Lee, Y. C., and Kawasaki, T. (1995) The differences in structural specificity for recognition and binding between asialoglycoprotein receptors of liver and macrophages. *Glycoconjugate J.* 12, 268–274.

(19) Suzuki, N., Yamamoto, K., Toyoshima, S., Osawa, T., and Irimura, T. (1996) Molecular cloning and expression of cDNA encoding human macrophage C-type lectin. Its unique carbohydrate binding specificity for Tn antigen. *J. Immunol.* 156, 128–135.

(20) Iida, S., Yamamoto, K., and Irimura, T. (1999) Interaction of human macrophage C-type lectin with O-linked N-acetylgalactosamine residues on mucin glycopeptides. J. Biol. Chem. 274, 10697– 10705.

(21) Marcelo, F., Garcia-Martin, F., Matsushita, T., Sardinha, J., Coelho, H., Oude-Vrielink, A., Koller, C., André, S., Cabrita, E. J., Gabius, H.-J., Nishimura, S., Jiménez-Barbero, J., and Cañada, F. J. (2014) Delineating binding modes of Gal/GalNAc and structural elements of the molecular recognition of tumor-associated mucin glycopeptides by the human macrophage galactose-type lectin. *Chem.* - *Eur. J.* 20, 16147–16155.

(22) Mortezai, N., Behnken, H. N., Kurze, A. K., Ludewig, P., Buck, F., Meyer, B., and Wagener, C. (2013) Tumor-associated NeuSAc-Tn and NeuSGc-Tn antigens bind to C-type lectin CLEC10A (CD301, MGL). *Glycobiology* 23, 844–852.

(23) Artigas, G., Monteiro, J. T., Hinou, H., Nishimura, S. I., Lepenies, B., and Garcia-Martin, F. (2017) Glycopeptides as targets for dendritic cells: exploring MUC1 glycopeptides binding profile toward macrophage galactose-type lectin (MGL) orthologs. *J. Med. Chem.* 60, 9012–9021.

(24) Dam, T. K., Gerken, T. A., Cavada, B. S., Nascimento, K. S., Moura, T. R., and Brewer, C. F. (2007) Binding studies of  $\alpha$ -GalNAcspecific lectins to the  $\alpha$ -GalNAc (Tn-antigen) form of porcine submaxillary mucin and its smaller fragments. *J. Biol. Chem.* 282, 28256–28263.

(25) Dam, T. K., Gerken, T. A., and Brewer, C. F. (2009) Thermodynamics of multivalent carbohydrate-lectin cross-linking interactions: importance of entropy in the bind and jump mechanism. *Biochemistry* 48, 3822–3827.

(26) Singh, Y., Rodriguez Benavente, M. C., Al-Huniti, M. H., Beckwith, D., Ayyalasomayajula, R., Patino, E., Miranda, W. S., Wade, A., and Cudic, M. (2020) Positional scanning MUC1 glycopeptide library reveals the importance of PDTR epitope glycosylation for lectin binding. J. Org. Chem. 85, 1434–1445.

(27) Kaltner, H., Manning, J. C., García Caballero, G., Di Salvo, C., Gabba, A., Romero-Hernández, L. L., Knospe, C., Wu, D., Daly, H. C., O'Shea, D. F., Gabius, H.-J., and Murphy, P. V. (2018) Revealing biomedically relevant cell and lectin type-dependent structure-activity profiles for glycoclusters by using tissue sections as an assay platform. *RSC Adv.* 8, 28716–28735.

(28) Dam, T. K., Oscarson, S., Sacchettini, J. C., and Brewer, C. F. (1998) Differential solvation of "core" trimannoside complexes of the *Dioclea grandiflora* lectin and concanavalin A detected by primary solvent isotope effects in isothermal titration microcalorimetry. *J. Biol. Chem.* 273, 32826–32832.

(29) Chervenak, M. C., and Toone, E. J. (1994) A direct measure of the contribution of solvent reorganization to the enthalpy of binding. *J. Am. Chem. Soc.* 116, 10533–10539.

(30) Wang, T., and Demchenko, A. V. (2019) Synthesis of carbohydrate building blocks via regioselective uniform protection/ deprotection strategies. *Org. Biomol. Chem.* 17, 4934–4950.

(31) Plattner, C., Hofener, M., and Sewald, N. (2011) One-pot azidochlorination of glycals. *Org. Lett.* 13, 545–547.

(32) Menges, F. (2020) Spectragryph - optical spectroscopy software, ver. 1.2 (http://www.effemm2.de/spectragryph/).

(33) Sato, M., Kawakami, K., Osawa, T., and Toyoshima, S. (1992) Molecular cloning and expression of cDNA encoding a galactose/ *N*acetylgalactosamine-specific lectin on mouse tumoricidal macrophages. *J. Biochem.* 111, 331–336.

(34) Kopitz, J., Vértesy, S., André, S., Fiedler, S., Schnölzer, M., and Gabius, H.-J. (2014) Human chimera-type galectin-3: Defining the critical tail length for high-affinity glycoprotein/cell surface binding and functional competition with galectin-1 in neuroblastoma cell growth regulation. *Biochimie 104*, 90–99.

(35) García Caballero, G., Flores-Ibarra, A., Michalak, M., Khasbiullina, N., Bovin, N. V., André, S., Manning, J. C., Vértesy, S., Ruiz, F. M., Kaltner, H., Kopitz, J., Romero, A., and Gabius, H.-J. (2016) Galectin-related protein: An integral member of the network of chicken galectins. 1. From strong sequence conservation of the gene confined to vertebrates to biochemical characteristics of the chicken protein and its crystal structure. *Biochim. Biophys. Acta, Gen. Subj.* 1860, 2285–2297.

(36) Michalak, M., Warnken, U., André, S., Schnölzer, M., Gabius, H.-J., and Kopitz, J. (2016) Detection of proteome changes in human colon cancer induced by cell surface binding of growth-inhibitory human galectin-4 using quantitative SILAC-based proteomics. J. Proteome Res. 15, 4412-4422.

(37) Diercks, T., Medrano, F. J., FitzGerald, F. G., Beckwith, D., Pedersen, M. J., Reihill, M., Ludwig, A.-K., Romero, A., Oscarson, S., Cudic, M., and Gabius, H.-J. (2021) Galectin-glycan interaction: guideline for monitoring by 77Se NMR spectroscopy and solvent ( $H_2O/D_2O$ ) impact on binding. *Chem. - Eur. J.* 27, 316–325.

(38) ITC data analysis in Origin. Tutorial Guide, ver. 7 (2004) MicroCal.

(39) Kutzner, T. J., Gabba, A., FitzGerald, F. G., Shilova, N. V., García Caballero, G., Ludwig, A.-K., Manning, J. C., Knospe, C., Kaltner, H., Sinowatz, F., Murphy, P. V., Cudic, M., Bovin, N. V., and Gabius, H.-J. (2019) How altering the modular architecture affects aspects of lectin activity: case study on human galectin-1. *Glycobiology* 29, 593–607.

(40) García Caballero, G., Beckwith, D., Shilova, N. V., Gabba, A., Kutzner, T. J., Ludwig, A.-K., Manning, J. C., Kaltner, H., Sinowatz, F., Cudic, M., Bovin, N. V., Murphy, P. V., and Gabius, H.-J. (2020) Influence of protein (human galectin-3) design on aspects of lectin activity. *Histochem. Cell Biol.* 154, 135–153.

(41) Keller, S., Vargas, C., Zhao, H., Piszczek, G., Brautigam, C. A., and Schuck, P. (2012) High-precision isothermal titration calorimetry with automated peak-shape analysis. *Anal. Chem.* 84, 5066–5073.

(42) Scheuermann, T. H., and Brautigam, C. A. (2015) Highprecision, automated integration of multiple isothermal titration calorimetric thermograms: new features of NITPIC. *Methods* 76, 87– 98.

(43) Burnouf, D., Ennifar, E., Guedich, S., Puffer, B., Hoffmann, G., Bec, G., Disdier, F., Baltzinger, M., and Dumas, P. (2012) KinITC: a new method for obtaining joint thermodynamic and kinetic data by isothermal titration calorimetry. *J. Am. Chem. Soc.* 134, 559–565.

(44) Dumas, P., Ennifar, E., Da Veiga, C., Bec, G., Palau, W., Di Primo, C., Piñeiro, A., Sabin, J., Muñoz, E., and Rial, J. (2016) Extending ITC to kinetics with kinITC. *Methods Enzymol.* 567, 157–180.

(45) Nigudkar, S. S., and Demchenko, A. V. (2015) Stereocontrolled 1,2-*cis* glycosylation as the driving force of progress in synthetic carbohydrate chemistry. *Chem. Sci.* 6, 2687–2704.

(46) Tripet, B., Cepeniene, D., Kovacs, J. M., Mant, C. T., Krokhin, O. V., and Hodges, R. S. (2007) Requirements for prediction of peptide retention time in reversed-phase high-performance liquid chromatography: hydrophilicity/hydrophobicity of side-chains at the N- and C-termini of peptides are dramatically affected by the end-groups and location. J. Chromatogr. A 1141, 212–225.

(47) Lopes, J. L., Miles, A. J., Whitmore, L., and Wallace, B. A. (2014) Distinct circular dichroism spectroscopic signatures of polyproline II and unordered secondary structures: applications in secondary structure analyses. *Protein Sci.* 23, 1765–1772.

(48) Jégouzo, S. A., Quintero-Martínez, A., Ouyang, X., dos Santos, Á., Taylor, M. E., and Drickamer, K. (2013) Organization of the extracellular portion of the macrophage galactose receptor: A trimeric cluster of simple binding sites for N-acetylgalactosamine. *Glycobiology* 23, 853–864.

(49) Pirro, M., Rombouts, Y., Stella, A., Neyrolles, O., Burlet-Schiltz, O., van Vliet, S. J., de Ru, A. H., Mohammed, Y., Wuhrer, M., van Veelen, P. A., and Hensbergen, P. J. (2020) Characterization of macrophage galactose-type lectin (MGL) ligands in colorectal cancer cell lines. *Biochim. Biophys. Acta, Gen. Subj.* 1864, 129513.

(50) Reynolds, M., and Pérez, S. (2011) Thermodynamics and chemical characterization of protein-carbohydrate interactions: the multivalency issue. C. R. Chim. 14, 74–95.

(51) Lee, R. T., and Lee, Y. C. (2000) Affinity enhancement by multivalent lectin-carbohydrate interaction. *Glycoconjugate J.* 17, 543–551.

(52) Adzhubei, A. A., and Sternberg, M. J. (1993) Left-handed polyproline II helices commonly occur in globular proteins. *J. Mol. Biol.* 229, 472–493.

(53) André, S., O'Sullivan, S., Koller, C., Murphy, P. V., and Gabius, H.-J. (2015) Bi- to tetravalent glycoclusters presenting GlcNAc/ GalNAc as inhibitors: from plant agglutinins to human macrophage galactose-type lectin (CD301) and galectins. *Org. Biomol. Chem. 13*, 4190–4203.

(54) Zihlmann, P., Silbermann, M., Sharpe, T., Jiang, X., Muhlethaler, T., Jakob, R. P., Rabbani, S., Sager, C. P., Frei, P., Pang, L., Maier, T., and Ernst, B. (2018) KinITC-one method supports both thermodynamic and kinetic SARs as exemplified on FimH antagonists. *Chem. - Eur. J.* 24, 13049–13057.

(55) Wild, M. K., Huang, M. C., Schulze-Horsel, U., van der Merwe, P. A., and Vestweber, D. (2001) Affinity, kinetics, and thermodynamics of E-selectin binding to E-selectin ligand-1. *J. Biol. Chem.* 276, 31602–31612.

(56) Hadjialirezaei, S., Picco, G., Beatson, R., Burchell, J., Stokke, B. T., and Sletmoen, M. (2017) Interactions between the breast cancerassociated MUC1 mucins and C-type lectin characterized by optical tweezers. *PLoS One 12*, No. e0175323.

(57) Toone, E. J. (1994) Structure and energetics of proteincarbohydrate complexes. *Curr. Opin. Struct. Biol.* 4, 719–728.

(58) Cioni, P., and Strambini, G. B. (2002) Effect of heavy water on protein flexibility. *Biophys. J.* 82, 3246–3253.

(59) Dam, T. K., Torres, M., Brewer, C. F., and Casadevall, A. (2008) Isothermal titration calorimetry reveals differential binding thermodynamics of variable region-identical antibodies differing in constant region for a univalent ligand. *J. Biol. Chem.* 283, 31366–31370.

(60) Dam, T. K., Gerken, T. A., and Brewer, C. F. (2009) Thermodynamics of multivalent carbohydrate-lectin cross-linking interactions: importance of entropy in the bind and jump mechanism. *Biochemistry* 48, 3822–3827.